Sionna Therapeutics (NASDAQ:SION) Director Sells $5,475,561.00 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 169,260 shares of the stock in a transaction that occurred on Thursday, October 16th. The shares were sold at an average price of $32.35, for a total transaction of $5,475,561.00. Following the completion of the sale, the director directly owned 722,301 shares of the company’s stock, valued at approximately $23,366,437.35. This trade represents a 18.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Bruce Booth also recently made the following trade(s):

• On Tuesday, October 21st, Bruce Booth sold 88,878 shares of Sionna Therapeutics stock. The stock was sold at an average price of $34.22, for a total transaction of $3,041,405.16.
• On Monday, October 20th, Bruce Booth sold 55,985 shares of Sionna Therapeutics stock. The shares were sold at an average price of $32.09, for a total transaction of $1,796,558.65.
• On Friday, October 17th, Bruce Booth sold 61,124 shares of Sionna Therapeutics stock. The shares were sold at an average price of $32.37, for a total transaction of $1,978,583.88.
• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.61, for a total transaction of $3,546,352.16.
• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.38, for a total transaction of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.98, for a total transaction of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total transaction of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $5,990.00.

Sionna Therapeutics Stock Down 8.5%

SION opened at $38.90 on Thursday. The company has a 50-day simple moving average of $26.55 and a 200 day simple moving average of $19.06. Sionna Therapeutics, Inc. has a twelve month low of $7.26 and a twelve month high of $43.19.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Monday, August 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.27.

Institutional Trading of Sionna Therapeutics

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new stake in shares of Sionna Therapeutics during the second quarter worth about $31,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Sionna Therapeutics during the 2nd quarter worth approximately $45,000. Virtus Investment Advisers LLC purchased a new stake in Sionna Therapeutics in the 2nd quarter valued at approximately $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Sionna Therapeutics in the 2nd quarter valued at $117,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Sionna Therapeutics in the 2nd quarter worth $118,000.

Analysts Set New Price Targets

Several research firms have commented on SION. Royal Bank Of Canada initiated coverage on Sionna Therapeutics in a report on Wednesday, September 3rd. They issued a “sector perform” rating and a $22.00 target price on the stock. Raymond James Financial assumed coverage on Sionna Therapeutics in a research report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $45.00 price target for the company. Jones Trading started coverage on Sionna Therapeutics in a research note on Monday, September 8th. They issued a “buy” rating and a $46.00 price objective for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Sionna Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.